NASDAQ:KROS Keros Therapeutics (KROS) Stock Price, News & Analysis $11.08 -0.09 (-0.81%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$11.10 +0.02 (+0.18%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Keros Therapeutics Stock (NASDAQ:KROS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Keros Therapeutics alerts:Sign Up Key Stats Today's Range$11.03▼$11.3450-Day Range$9.97▼$12.0352-Week Range$9.69▼$22.55Volume143,825 shsAverage Volume163,570 shsMarket Capitalization$219.68 millionP/E RatioN/ADividend YieldN/APrice Target$20.50Consensus RatingHold Company Overview Keros Therapeutics, Inc. (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need. The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis. KER-050 is currently being evaluated in multiple clinical trials across North America and Europe. In parallel, Keros is advancing additional preclinical programs that leverage its proprietary platform to address other hematologic and iron-related disorders. Founded in 2019 as a spin-out from academic research, Keros Therapeutics is headquartered in Boston, Massachusetts, and collaborates with leading research institutions and clinical centers worldwide. The company’s leadership team comprises industry veterans in research and development, clinical operations and regulatory affairs, all focused on translating groundbreaking science into therapies that improve patient outcomes in serious blood diseases.AI Generated. May Contain Errors. Read More Keros Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreKROS MarketRank™: Keros Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 202nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingKeros Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 4 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialKeros Therapeutics has a consensus price target of $20.50, representing about 85.0% upside from its current price of $11.08.Amount of Analyst CoverageKeros Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Keros Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Keros Therapeutics are expected to decrease in the coming year, from ($5.27) to ($6.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Keros Therapeutics is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Keros Therapeutics is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Keros Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.72% of the float of Keros Therapeutics has been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 6.09.Change versus previous monthShort interest in Keros Therapeutics has recently increased by 1.40%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.19 News SentimentKeros Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Keros Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for KROS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have sold 439.60% more of their company's stock than they have bought. Specifically, they have bought $10,190.00 in company stock and sold $54,985.00 in company stock.Percentage Held by Insiders12.60% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Keros Therapeutics' insider trading history. Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KROS Stock News HeadlinesKeros Therapeutics (NASDAQ:KROS) Board Announces Share Repurchase ProgramSeptember 11 at 1:10 AM | americanbankingnews.comKeros Therapeutics Authorises $ 5 Mln Share Buyback Following Elritercept Milestone; Stock UpSeptember 9 at 7:35 AM | rttnews.comThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, and Millennium by 122%. Kopernik Global made it their largest holding, owning roughly 8% of the company. It holds rights to an 88 million ounce deposit with existing roads, power, and permits that never expire. Market cap sits near $4 billion against a deposit worth hundreds of billions at current gold prices. | Behind the Markets (Ad)Keros Therapeutics Approves $5 Million Share BuybackSeptember 8, 2026 | marketscreener.comMKeros Therapeutics Announces $5 Million Share Repurchase AuthorizationSeptember 8, 2026 | globenewswire.comWall Street Zen Downgrades Keros Therapeutics (NASDAQ:KROS) to Strong SellSeptember 5, 2026 | americanbankingnews.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by AnalystsSeptember 4, 2026 | americanbankingnews.comInsider Selling: Keros Therapeutics (NASDAQ:KROS) VP Sells $12,594.96 in StockAugust 21, 2026 | insidertrades.comSee More Headlines KROS Stock Analysis - Frequently Asked Questions How have KROS shares performed this year? Keros Therapeutics' stock was trading at $20.36 at the beginning of 2026. Since then, KROS stock has decreased by 45.6% and is now trading at $11.08. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) released its earnings results on Monday, August, 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by $0.11. Keros Therapeutics had a negative net margin of 256.60% and a negative trailing twelve-month return on equity of 21.40%. Is Keros Therapeutics doing a stock buyback? Keros Therapeutics' Board of Directors initiated a stock repurchase program on Wednesday, September 9th 2026, which authorizes the company to buy back $5,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 2.3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its shares are undervalued. When did Keros Therapeutics IPO? Keros Therapeutics (KROS) raised $90 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Keros Therapeutics' major shareholders? Keros Therapeutics' top institutional shareholders include BlackRock Inc. (14.09%), Nantahala Capital Management LLC (7.11%), ADAR1 Capital Management LLC (1.24%) and Man Group plc (0.78%). Insiders that own company stock include Carl L Gordon, Carl L Gordon, Annita Tanini, Lorena Raquel Lerner, Jean Jacques Bienaime, Charles W Newton, Julius Knowles, Alpna Seth, Nima Farzan, Pontifax Management 4 GP (20 and Adar1 Capital Management, Llc. View institutional ownership trends. How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings8/03/2026Today9/11/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 KROS's financial health is in the Red zone, according to TradeSmith. KROS has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KROS CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees100Year Founded2015Price Target and Rating Average Price Target for Keros Therapeutics$20.50 High Price Target$27.00 Low Price Target$16.00 Potential Upside/Downside+85.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$87.01 million Net Margins-256.60% Pretax Margin-573.45% Return on Equity-21.40% Return on Assets-19.79% Debt Debt-to-Equity RatioN/A Current Ratio21.96 Quick Ratio21.96 Sales & Book Value Annual Sales$15.01 million Price / Sales14.63 Cash Flow$4.49 per share Price / Cash Flow2.47 Book Value$15.51 per share Price / Book0.71Miscellaneous Outstanding Shares19,827,000Free Float17,329,000Market Cap$219.68 million OptionableOptionable Beta1.01 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:KROS) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...Decentralized Masters | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
